GC Wealth Management RIA LLC Makes New Investment in TransMedics Group, Inc. $TMDX

Key Points

• GC Wealth Management RIA LLC has purchased 2,771 shares of TransMedics Group, valued at approximately $371,000, indicating growing institutional interest in the company.
• TransMedics Group recently reported a quarterly earnings per share of $0.92, significantly beating the expected $0.48, and achieved a revenue of $157.37 million, which exceeded consensus estimates.
• Analysts have positively revised their price targets for TransMedics Group, with firms like Morgan Stanley and Oppenheimer suggesting potential upsides to $150.00 and $123.00 respectively, reflecting an overall Moderate Buy consensus rating.

GC Wealth Management RIA LLC purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,771 shares of the company's stock, valued at approximately $371,000.

Several other institutional investors also recently added to or reduced their stakes in TMDX. Two Sigma Investments LP acquired a new position in shares of TransMedics Group in the fourth quarter valued at approximately $781,000. GAMMA Investing LLC increased its holdings in shares of TransMedics Group by 43,744.2% in the first quarter. GAMMA Investing LLC now owns 105,226 shares of the company's stock valued at $7,080,000 after purchasing an additional 104,986 shares during the period. NBC Securities Inc. acquired a new position in shares of TransMedics Group in the first quarter valued at approximately $25,000. Sugar Maple Asset Management LLC acquired a new position in shares of TransMedics Group in the first quarter valued at approximately $740,000. Finally, SG Americas Securities LLC increased its holdings in shares of TransMedics Group by 132.2% in the first quarter. SG Americas Securities LLC now owns 14,126 shares of the company's stock valued at $950,000 after purchasing an additional 8,043 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Stock Up 2.4%

TransMedics Group stock opened at $114.89 on Thursday. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $147.67. The company has a market cap of $3.92 billion, a PE ratio of 59.53 and a beta of 2.08. The stock's 50 day moving average price is $116.67 and its 200 day moving average price is $109.67.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TMDX. Morgan Stanley boosted their target price on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. Oppenheimer boosted their target price on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Canaccord Genuity Group boosted their target price on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Zacks Research raised TransMedics Group from a "hold" rating to a "strong-buy" rating in a report on Monday. Finally, Evercore ISI began coverage on TransMedics Group in a research note on Tuesday, September 16th. They issued an "outperform" rating and a $155.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $125.40.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.